Detalhe da pesquisa
1.
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
Diabetes Obes Metab
; 26(3): 851-859, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082473
2.
Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
Diabetes Obes Metab
; 25(9): 2526-2534, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37253689
3.
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
Diabetes Obes Metab
; 25(3): 656-663, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309941
4.
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Diabetes Obes Metab
; 22(9): 1664-1669, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32314521
5.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Diabetes Obes Metab
; 22(8): 1369-1377, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32243043
6.
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Diabetes Obes Metab
; 22(3): 346-354, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31646724
7.
Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis.
Ann Allergy Asthma Immunol
; 124(6): 616-621.e3, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32004698
8.
Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment.
Diabetes Obes Metab
; 20(12): 2860-2868, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30003642
9.
Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.
Diabetes Res Clin Pract
; 209: 111604, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447911
10.
Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study.
Diabetes Res Clin Pract
; 209: 111567, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341039
11.
Patient-reported outcomes and treatment adherence in type 2 diabetes using natural language processing: Wave 8 of the Observational International Diabetes Management Practices Study.
J Diabetes Investig
; 2024 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38840439
12.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Mult Scler J Exp Transl Clin
; 8(4): 20552173221135888, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36407472
13.
Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
Diabetes Res Clin Pract
; 142: 19-25, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649539
14.
Management of bipolar disorder in the intercontinental region: an international, multicenter, non-interventional, cross-sectional study in real-life conditions.
Sci Rep
; 6: 25920, 2016 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27181262